Creating New Businesses Through Data-Driven Business and Open Innovation
First written in FY2021. 3 of 5 entries say "Advanced", first in FY2023. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「The company will combine its extensive testing data, built on a customer base spanning more than 190 countries worldwide, with AI analysis technologies to provide proprietary Sysmex healthcare DX solutions.」
The company made its policy on data businesses using testing data and clinical information and open innovation more concrete through healthcare DX solutions combining testing data from its customer base with AI analysis. - 2026-05-14AdvancedRevisions to earnings forecasts
「Promoting healthcare DX and data utilization by leveraging the strengths of the diagnostics business」
Healthcare DX and data utilization were explicitly identified as key themes of the new medium-term management plan. - FY2024RestatedAnnual report
「The company will also promote open innovation aimed at implementing innovative digital technologies in society and healthcare, and pursue the creation of new businesses through the use of healthcare data.」
The company has restated its policy of creating new businesses through the use of healthcare data and open innovation. - FY2023AdvancedAnnual report
「The company will also promote open innovation aimed at implementing innovative digital technologies in society and healthcare, and pursue the creation of new businesses through the use of healthcare data.」
The company made its data business using testing data and clinical information and its open innovation policy more concrete by focusing on the creation of new businesses through the use of healthcare data. - FY2021First statedAnnual report
「The company will also promote research and development, primarily in data businesses that use testing data and clinical information, and pursue the creation of new businesses through open innovation aimed at early commercialization and the acquisition of core technologies.」
The company first explicitly identified data businesses using testing data and clinical information, and open innovation aimed at early commercialization and acquiring core technologies, as means of creating new businesses.